Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Ambros Therapeutics to merge with Werewolf Therapeutics

RECENTLY ACQUIREDAug 21, 2026•about 3 hours ago

Acquiring Company

Ambros Therapeutics

Acquired Company

Werewolf Therapeutics

IrvineWatertownBiotechnologyHealth CareTherapeuticsBiotechnologyHealthcareHealth CareTherapeutics

Description

Werewolf Therapeutics and Ambros Therapeutics have entered a definitive all-stock merger agreement to form a Nasdaq-listed biotechnology company. The merger will enable the combined entity to focus on developing neridronate for Complex Regional Pain Syndrome Type 1. The transaction is expected to close by the first quarter of 2027, subject to appropriate approvals. Existing shareholders will receive a stake in the new company and potential value tied to legacy assets.

Company Information

Company

Ambros Therapeutics

Location

Irvine, California, United States

About

Ambros Therapeutics is a biotech firm focused on developing a non-opioid pain medicine for Complex Regional Pain Syndrome type 1 (CRPS-1). Co-founded by Vivek Ramaswamy and industry veteran Keith Katkin, the company has secured $125 million in series A funding to support a pivotal phase 3 trial of its lead candidate, neridronate. The drug has a history of use in Italy since 2014 and aims to provide an alternative treatment solution for patients suffering from this rare disease. With a seasoned leadership team, Ambros seeks to advance its therapy through partnership with Abiogen Pharma.

Don't miss Ambros Therapeutics's next move

Get an email the moment Ambros Therapeutics makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Michael
Likely contact at this company
••••••••@••••••••

See Michael's verified email →

Jennifer
Likely contact at this company
••••••••@••••••••

See Jennifer's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for Ambros Therapeutics's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Werewolf Therapeutics?

Werewolf Therapeutics was acquired by Ambros Therapeutics, based in Irvine. The deal was reported on August 21, 2026. Ambros Therapeutics is a biotech firm focused on developing a non-opioid pain medicine for Complex Regional Pain Syndrome type 1 (CRPS-1). Ambros Therapeutics is privately held and operates in Biotechnology.

When did Ambros Therapeutics acquire Werewolf Therapeutics?

Ambros Therapeutics's acquisition of Werewolf Therapeutics was reported on August 21, 2026. Werewolf Therapeutics and Ambros Therapeutics have entered a definitive all-stock merger agreement to form a Nasdaq-listed biotechnology company. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Werewolf Therapeutics do?

Werewolf Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. It is publicly traded (HOWL), operating in Biotechnology, and is based in Watertown.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.